Guest Articles
Eye Drop Problems - Part 1
- Written by Andrew D Price
Eye Drop Problems - Part 1 (warning not for the faint hearted!)
For a many months now I have been aware that when it comes to over the counter (OTC) dry eye drops in the USA things were not quite as benign as one would expect, storms have been blowing across the landscape, primarily associated with a perceived relaxed approach to regulatory over-sight of eye drop safety and claimed health benefits, this has involved more than a handful of products and manufacturers.
Clinical Insights 3
- Written by Prof John Nolan
The Body Doctor Clinical Insights
Patented Supplements for eye health & AMD
Researched by Prof. John Nolan who has spent over 25 years researching carotenoids at the Nutrition Research Centre Ireland. This product range is exclusively distributed by The Body Doctor Ltd.
Read more...
Addressing Contact Lens Symptoms with Meibomian Gland home treatment
- Written by Andrew D Price
Later day contact lens discomfort is a frequent complaint amongst contact lens wearers. Historically treatments have been approached from the direction of lens design changes, often frequently and almost as often with little or no success. This trial used the CLDEQ-8 to query the frequency and intensity of 5 symptoms associated with contact lens discomfort, subjective scores, and clinical measures to assess the response to the planned treatments.
The results indicated that improving Meibomian Gland function can produce statistically significant improvements in the frequency, severity, and overall sum of subjective symptoms associated with dryness among SCL wearers, and therefore may reduce contact lens discomfort, aid patient retention and reduce contact lens drop-out.
I would encourage you to look especially at the CLDEQ-8 results and subject comments. The trial was funded by a grant from The Body Doctor Limited. Further product information can be obtained from The Body Doctor Limited by email This email address is being protected from spambots. You need JavaScript enabled to view it. Discussion on the clinical trial welcomed email This email address is being protected from spambots. You need JavaScript enabled to view it.
The ADP Consultancy Portfolio
- Written by Andrew D Price
The ADP Consultancy Portfolio
May I introduce myself and my consultancy? Mr Andrew D Price FBDO(Hons)CL MBCLA, CEO of The ADP Consultancy originally set-up in 1994. A clinician, seeing patients in Contact Lens & Ocular Surface clinics (clinics in your practice available – see page 8), Principal Investigator in clinical trials, industry/Professional Services Consultant, educator, lecturer and author.
Holding Honours Fellowship of the Association of British Dispensing Opticians (ABDO) in Contact Lens Practice. I have received Certification
in Ophthalmic Assisting during my work in ophthalmology practice in the USA. Experience encompasses managing/owning my own contact lens
practice, working in practice in Laser Vision and Ophthalmology clinics in the UK and USA. I have had many articles published and presented
over three hundred lectures and workshops on the subjects of contact lenses and dry eye disease. Working with others, my consultancy has a
website devoted to the ocular surface with separate Professional and Patient Sections Eye Drops Database (EDDB)
I am a past ABDO National Clinical Committee and Optometry Wales Board member, still involved in numerous projects. Also VTI European
Professional Affairs Consultant and Head of Professional Services for The Body Doctor Ltd. Member of the British Contact Lens Association
(BCLA).
As a consultancy we have published clinical trial reports, articles and conference posters on multi-focal and toric contact lenses, and punctal
occlusion/contact lens discomfort. We have worked with JnJ Vision Care, Thea Pharma and others worldwide.
I was an investigator in a diabetic clinical study for Duke University in the USA. Pioneered first clinical audit in UK Laser Vision Clinic on treatment outcomes. Developed world’s first ever IT subscription system delivering up-to-date data on CLs, solutions and ocular therapeutics, provided to UK ECPs, universities, laboratories.
Delivered live radio ‘phone-ins’ and webinars on CL and DE subjects and produced journal articles on eye-care and CLs. Continuing to grow, July
2018 Sue Waller took up the role of Executive Administrator, bringing many years Senior Administrator experience.
Read more...
The Eye Doctor Clinical InSights
- Written by Martin Blasczyk
The Eye Doctor Clinical InSights
HAY FEVER FORECAST: Itchy eyes ahead
Most of us are overly familiar with the streaming eyes, endless sneezing and congested sinuses that come paired with the Great British Summer, but what’s not as well known is that Hay Fever can affect us all year round. Hay fever occurs when your immune system overreacts to an outdoor allergen. The most common allergens are pollens from wind-pollinated plants, such as trees, grass and weeds. The pollen from insect-pollinated plants are too heavy to remain airborne for long, and they’re less likely to trigger an allergic reaction. Seasonal allergies are less common during the winter, but it’s possible to experience an allergic reaction rhinitis year-round due to different plants emitting their respective pollens at different times of the year.
Read more...
The Eye Doctor Clinical InSights
- Written by Andrew D Price
The Eye Doctor Clinical InSights
Supplementing Against Dry Eye Disease
- Written by Dr Patrick Herve, Managing Director, Lagad Vision Laboratory Ltd
Up to 38 per cent of the general population suffers from a degree of dry eye, according to the latest figures from the American Academy of Ophthalmology presented in Chicago in 2012. There is a dry eye epidemic in people aged between 15 and 25 years due to the extensive use of amartphones, video games, tablets, etc. More than 50 per cent of the presbyopic population is affected. This means that, overall, more than 50 per cent of opticans’ customers would greatly benefit from an effective treatment to alleviate their symptoms and improve their quality of life. Read the full article and post your thoughts/comments/questions in The Forum!
How to grow the Ortho-K market? Call them ‘Night Lenses’
- Written by Tom Griffiths, Managing Director, Scotlens
How to grow the Ortho-K market? Call them ‘Night Lenses’
|
Nobody discusses their successful Photorefractive Keratectomy with friends… |
Nobody discusses their successful Photorefractive Keratectomy with friends, or on facebook asks whether to have Laser-Assisted In Situ Keratomileusis. Neither do they say “LASIK changed my life”, which ECP’s know is the abbreviated form for the latter. They talk about ‘Laser eye surgery’. Do they know how it works? Not at all. But they know the difference it will make to their lives despite the risks they openly discuss on social forums. Agreed phraseology over social media and effective communication between patients and the industry has helped to create a global ‘laser eye surgery’ industry worth in excess of $3.5bn.
Mr. Reza Ahmadi Choubdar
- Written by Mr. Reza Ahmadi Choubdar
| Mr. Reza Ahmadi Choubdar Optometrist |
This email address is being protected from spambots. You need JavaScript enabled to view it. Cardiff, Wales |
An accomplished eye care professional with 26 years of excellent experience assisting customers in optimum frames and lenses selection and fitting of contact lens. Adept at assisting patient select and size frames and lenses based on prescriptions from ophthalmologists or optometrists. Expert in evaluating prescriptions, obtaining eye measurements, and securing fitting information while ensuring accuracy and attention to detail.
DOORS Press Release
- Written by Andrew D Price
DOORS Press Release
A new health study is to be launched in a bid to help millions who suffer from ‘dry eye’.
One in four of us will suffer from the debilitating condition with symptoms ranging from sore eyes through to short-term blurred vision.
Now experts based in Birmingham and Nottingham are looking for people to take part in the study, wearing a special contact lens for under 2 weeks, which could lead to longer term relief.